Stock Traders Purchase High Volume of Call Options on AxoGen (NASDAQ:AXGN)

AxoGen, Inc. (NASDAQ:AXGN) was the recipient of unusually large options trading activity on Wednesday. Investors acquired 9,886 call options on the stock. This is an increase of approximately 998% compared to the typical volume of 900 call options.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Earnings beat and higher guidance: AxoGen reported third-quarter earnings of $0.21 per share, exceeding consensus estimates of $0.13-$0.14 and improving from $0.12 a year earlier. Revenue reached approximately $75.8 million, also ahead of expectations. Management raised its 2026 revenue outlook to $290 million, reinforcing expectations for continued growth. AxoGen Shares Gap Up After Earnings Beat AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Broad analyst optimism: Canaccord Genuity raised its target from $55 to $60 and kept a Buy rating. Truist increased its target from $53 to $60, while Wells Fargo lifted its target from $48 to $56 with an Overweight rating. HC Wainwright also raised its target from $53 to $56 and maintained a Buy rating. These revisions suggest analysts view the earnings performance and outlook as supporting additional upside. Truist Raises AxoGen Price Target
• Positive Sentiment: Strong investor interest: Trading activity included purchases of 9,886 AXGN call options, nearly 10 times the average daily volume, indicating heightened speculative and bullish interest following the results.
• Neutral Sentiment: Despite the earnings momentum, AxoGen remains unprofitable on a trailing basis, with a negative net margin and analysts forecasting a loss for the full fiscal year. The stock’s substantial advance toward its 52-week high may also leave it more sensitive to profit-taking.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Citigroup reissued a “market outperform” rating on shares of AxoGen in a research report on Thursday, July 30th. Truist Financial increased their price target on AxoGen from $53.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright raised their price target on AxoGen from $53.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday. Citizens Jmp boosted their price target on AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Thursday, July 30th. Finally, Barclays boosted their price target on AxoGen from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.92.

Insider Buying and Selling at AxoGen

In related news, Director Amy Wendell sold 13,353 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.42, for a total transaction of $646,552.26. Following the completion of the transaction, the director owned 107,976 shares in the company, valued at $5,228,197.92. The trade was a 11.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,503 shares of company stock valued at $4,656,947 in the last ninety days. Company insiders own 2.44% of the company’s stock.

Hedge Funds Weigh In On AxoGen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nykredit A S purchased a new stake in shares of AxoGen in the 2nd quarter worth approximately $30,000. KBC Group NV acquired a new position in shares of AxoGen during the first quarter valued at $41,000. Sterling Capital Management LLC increased its stake in shares of AxoGen by 858.9% in the third quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 1,589 shares during the period. State of Alaska Department of Revenue grew its position in AxoGen by 16.9% during the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock worth $118,000 after buying an additional 409 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in AxoGen in the second quarter valued at approximately $203,000. 80.29% of the stock is owned by institutional investors.

AxoGen Stock Up 0.8%

Shares of NASDAQ AXGN opened at $49.63 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The company has a market capitalization of $2.67 billion, a PE ratio of -76.35 and a beta of 1.17. The firm’s 50-day moving average is $42.80 and its two-hundred day moving average is $39.36. AxoGen has a 12-month low of $21.68 and a 12-month high of $52.91.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. AxoGen had a negative net margin of 11.96% and a negative return on equity of 7.18%. The business had revenue of $75.83 million for the quarter, compared to the consensus estimate of $73.45 million. Equities analysts anticipate that AxoGen will post -0.44 EPS for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.